Leisa Johnson

5.9k total citations · 1 hit paper
23 papers, 4.3k citations indexed

About

Leisa Johnson is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Leisa Johnson has authored 23 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Genetics. Recurrent topics in Leisa Johnson's work include Virus-based gene therapy research (6 papers), Cancer Cells and Metastasis (4 papers) and Cancer-related Molecular Pathways (4 papers). Leisa Johnson is often cited by papers focused on Virus-based gene therapy research (6 papers), Cancer Cells and Metastasis (4 papers) and Cancer-related Molecular Pathways (4 papers). Leisa Johnson collaborates with scholars based in United States, France and United Kingdom. Leisa Johnson's co-authors include Tyler Jacks, Kim L. Mercer, Roderick T. Bronson, Doron C. Greenbaum, David A. Tuveson, Denise Crowley, Wei‐Qiang Gao, Bu-Er Wang, Kevin G. Leong and Terry Hermiston and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Leisa Johnson

23 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

2001 906 citations Leisa Johnson, Kim L. Mercer et al. Nature profile →

Peers

Countries citing papers authored by Leisa Johnson

Since Specialization

Citations

This map shows the geographic impact of Leisa Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leisa Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leisa Johnson more than expected).

Fields of papers citing papers by Leisa Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leisa Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leisa Johnson. The network helps show where Leisa Johnson may publish in the future.

Co-authorship network of co-authors of Leisa Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Leisa Johnson. A scholar is included among the top collaborators of Leisa Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leisa Johnson. Leisa Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis 2015 ·Translational Oncology ·Kai Barck, Hani Bou-Reslan, (unknown), (unknown), Jason E. Long, Rafael Molina, (unknown), (unknown), Melissa R. Junttila, Leisa Johnson, Richard A.D. Carano	11
2	Abstract 2259: Requirement for BUB1B in tumor progression of lung adenocarcinoma 2015 ·Cancer Research ·Honglin Chen, James Lee, Noelyn M. Kljavin, Benjamin Haley, Anneleen Daemen, Yuxin Liang, Leisa Johnson	1
3	Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells 2014 ·Cancer & Metabolism ·Yuting Sun, Anneleen Daemen, Georgia Hatzivassiliou, David Arnott, Catherine Wilson, Guanglei Zhuang, Min Gao, Peter Liu, Aaron Boudreau, Leisa Johnson, Jeff Settleman	98
4	Genetically Engineered Knock-In and Conditional Knock-In Mouse Models of Cancer 2014 ·Cold Spring Harbor Protocols ·Amy Rappaport, Leisa Johnson	5
5	Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes 2012 ·Cancer Research ·Mallika Singh, Christopher L. Murriel, Leisa Johnson	91
6	Androgen Deprivation Causes Epithelial–Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy 2011 ·Cancer Research ·Yuting Sun, Bu-Er Wang, Kevin G. Leong, Yue Peng, Li Li, Suchit Jhunjhunwala, (unknown), Kyounghee Seo, Zora Modrušan, Wei‐Qiang Gao, Jeffrey Settleman, Leisa Johnson	287
7	Abstract 3295: Inhibiting vascular morphogenesis in tumors: EGFL7 as a novel therapeutic target 2011 ·Cancer Research ·(unknown), Tanya Smyczek, Jason Cheng, (unknown), Rafael Molina, (unknown), Jason E. Long, Leanne Berry, Michelle Nannini, Kai Barck, Hani Bou-Reslan, Tim C. Cao, Calvin Ho, Richard A.D. Carano, Ian Kasman, (unknown), Mallika Singh, Weilan Ye, Leisa Johnson	4
8	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models 2010 ·Nature Biotechnology ·Mallika Singh, (unknown), Rafael Molina, (unknown), (unknown), Vidusha Devasthali, Jennifer D. Thompson, Jason Cheng, Hani Bou Reslan, Calvin Ho, (unknown), Chingwei V. Lee, Michelle Nannini, Germaine Fuh, Richard A.D. Carano, Hartmut Koeppen, Ron Yu, William F. Forrest, Gregory D. Plowman, Leisa Johnson	175
9	Distinct Thresholds Govern Myc's Biological Output In Vivo 2008 ·Cancer Cell ·Daniel J. Murphy, Melissa R. Junttila, Laurent Pouyet, Anthony N. Karnezis, Ksenya Shchors, (unknown), Lamorna Brown Swigart, Leisa Johnson, Gérard I. Evan	340
10	Generation of a prostate from a single adult stem cell 2008 ·Nature ·Kevin G. Leong, Bu-Er Wang, Leisa Johnson, Wei‐Qiang Gao	332
11	Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective 2006 ·Clinical Cancer Research ·Mallika Singh, Leisa Johnson	60
12	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease 2004 ·Journal of Clinical Investigation ·Iris T. Chan, Jeffery L. Kutok, Ifor R. Williams, Sarah L. Cohen, Lauren S. Kelly, Hirokazu Shigematsu, Leisa Johnson, Koichi Akashi, David A. Tuveson, Tyler Jacks, D. Gary Gilliland	205
13	Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity 2004 ·Cancer Cell ·Clodagh C. O’Shea, Leisa Johnson, (unknown), Serah Choi, Cory R. Nicholas, Annie Shen, (unknown), Kusum Pandey, Conrado Soria, John Charles Kunich, Yuqiao Shen, Gaston Habets, (unknown), Frank McCormick	291
14	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease 2004 ·Journal of Clinical Investigation ·Iris T. Chan, Jeffery L. Kutok, Ifor R. Williams, Sarah Cohen, Lauren E. Kelly, Hirokazu Shigematsu, Leisa Johnson, Koichi Akashi, David A. Tuveson, Tyler Jacks, D. Gary Gilliland	21
15	Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents 2002 ·Cancer Cell ·Leisa Johnson, Annie Shen, (unknown), John Charles Kunich, Kusum Pandey, Marilyn J. Lemmon, Terry Hermiston, (unknown), Frank McCormick, Ali Fattaey	150
16	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice breakdown → 2001 ·Nature ·Leisa Johnson, Kim L. Mercer, Doron C. Greenbaum, Roderick T. Bronson, Denise Crowley, David A. Tuveson, Tyler Jacks	906
17	Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region 2001 ·Gene Therapy ·(unknown), Leisa Johnson, Maxine Bauzon, (unknown), Daniel Barros de Castro, (unknown), (unknown), (unknown), Patrick W. Trown, (unknown)	81
18	Wildtype Kras2 can inhibit lung carcinogenesis in mice 2001 ·Nature Genetics ·Zhongqiu Zhang, (unknown), Haris G. Vikis, Leisa Johnson, Gongjie Liu, Jie Li, M W Anderson, Robert C. Sills, Hao Le Thi Hong, Theodora R. Devereux, Tyler Jacks, Kun‐Liang Guan, Ming You	245
19	An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy 2000 ·Nature Medicine ·Carla Heise, Terry Hermiston, Leisa Johnson, Gabriel Brooks, Adam Sampson-Johannes, (unknown), (unknown), David H. Kirn	483
20	K-ras is an essential gene in the mouse with partial functional overlap with N-ras 1997 ·Genes & Development ·Leisa Johnson, Doron C. Greenbaum, Karen Cichowski, Kim L. Mercer, Elizabeth A. Murphy, Eric Schmitt, Roderick T. Bronson, (unknown), (unknown), Raju Kucherlapati, Tyler Jacks	449

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact